ConductScience.org, home

Trial · NCT07904962

Registered outcomes11

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

ListOutcomeTime frameDescription
PrimaryGlycated Hemoglobin (HbA1c) at Week 12Week 12
Glycated Hemoglobin (HbA1c) will be measured from a venous blood sample and reported as a percentage (%). The primary comparison will evaluate HbA1c at Week 12 between the randomized groups, with baseline HbA1c accounted for in the primary statistical analysis.
SecondaryFasting Plasma Glucose at Week 12Week 12Fasting plasma glucose will be measured from a venous blood sample after an overnight fast and reported in mmol/L.
Secondary2-Hour Plasma Glucose During the Oral Glucose Tolerance Test at Week 12Week 12Plasma glucose will be measured 120 minutes after ingestion of a 75-g oral glucose load and reported in mmol/L.
SecondaryNormal Glucose Regulation at Week 12Week 12
Normal glucose regulation will be defined as meeting all of the following criteria at Week 12: fasting plasma glucose \<5.6 mmol/L, 2-hour plasma glucose \<7.8 mmol/L during a 75-g oral glucose tolerance test, and glycated hemoglobin (HbA1c) \<5.7%. The outcome will be reported as the number and proportion of participants meeting these criteria.
SecondaryTotal Body Fat Percentage at Week 12Week 12Total body fat percentage will be assessed using dual-energy X-ray absorptiometry (DXA) and reported as a percentage (%).
SecondaryShort Physical Performance Battery Total Score at Week 12Week 12
Physical performance will be assessed using the Short Physical Performance Battery (SPPB), which includes standing balance, usual 4-meter walking speed, and five repeated chair stands. The total score ranges from 0 to 12 points, with higher scores indicating better physical performance.
OtherMatsuda Insulin Sensitivity Index at Week 12Week 12
The Matsuda insulin sensitivity index will be calculated from glucose and insulin concentrations measured during the 75-g oral glucose tolerance test at 0, 30, 60, 90, and 120 minutes. Higher values indicate greater insulin sensitivity.
OtherGlucose Coefficient of Variation From Continuous Glucose Monitoring at Week 1214-day monitoring period at Week 12
Glucose variability will be assessed using the coefficient of variation derived from continuous glucose monitoring data. Continuous glucose monitoring will be conducted in a prespecified exploratory subgroup.
OtherModerate-to-Vigorous Physical Activity at Week 127-day monitoring period at Week 12Moderate-to-vigorous physical activity will be assessed objectively using an ActiGraph GT3X accelerometer and summarized as average minutes per day during valid wear days.
OtherKnee Extensor Peak Torque at Week 12Week 12Knee extensor strength will be assessed using isokinetic dynamometry at 60°/s. Peak torque will be recorded in N·m, with bilateral measurements obtained according to the standardized testing protocol.
Other6-Minute Walk Distance at Week 12Week 12Functional exercise capacity will be assessed using the 6-minute walk test. The primary measure will be the total distance walked in 6 minutes, reported in meters.

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT07904962/registered